Prof Audrey Nosbaum is an expert in Dermatology at Centre Hospitalier Lyon Sud (France). As of September 2026, ScienceLeadR ranks Audrey Nosbaum in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and Skin Diseases, Eczematous. Audrey Nosbaum has authored 335 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 1,229 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Audrey Nosbaum Centre Hospitalier Lyon Sud France
1 229 ScienceLeadR Reputation 1229
Network Map

Dermatology

Subspecialties: Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

Claude Bernard University Lyon 1

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
PMID 42163822 — sexually transmitted diseases, dermatitis, eczema, immunoglobulin a, adolescent, dermatology, dermatitis, atopic, non-responder
Acta Derm Venereol20260
The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA 2LEN ADCARE statement paper.
PMID 42028244 — skin, dermatitis, adrenal cortex hormones, therapeutics, dermatitis, atopic
World Allergy Organ J20260
Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema.
PMID 41705342 — skin, dermatitis, hypersensitivity, eczema, immunity, therapeutics, psoriasis, dermatitis, atopic, dermatitis, contact
Allergy20260
Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Ra mAb.
PMID 41317962 — interleukin-5, hypersensitivity, eczema, therapeutics, asthma, dermatitis, atopic
J Allergy Clin Immunol Pract20250
[Dupilumab-associated head and neck dermatitis is associated with an overexpression of Interleukin 22].
PMID 41259704 — dermatitis
Med Sci (Paris)20250

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 6
Phase 3 5
Phase 2 3
Phase 4 1

By status:

Completed 7
Recruiting 3
Active not recruiting 2
Not yet recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 12
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 9

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE)
2025-522403-17-00 — safety, dermatitis, adrenal cortex hormones, eczema, therapeutics
Phase 3Recruiting2026
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia
2022-502047-35-00 — yellow fever vaccine, antibody formation, safety, vaccines, yellow fever
Phase 2Active not recruiting2021
Dupilumab step down strategy to maintain remission in adult and adolescents patients with atopic dermatitis a non inferiority randomized trial
2022-501179-23-00 — dermatitis, adolescent, dermatitis, atopic
Phase 4Active not recruiting2023
Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam Tool
NCT06351449 — skin, dermatitis, dermatitis, allergic contact, dermatitis, contact, patch tests
N/ANot yet recruiting2024
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis
NCT06239311 — injections, skin, safety, dermatitis, pharmaceutical preparations, solutions, counterfeit drugs, therapeutics, methotrexate, dermatitis, atopic
Phase 3Recruiting2024

LeadR Networks

Main global connection map